BioVie Inc. (BIVI)Healthcare | Biotechnology | Carson City, United States | NasdaqCM
1.58 USD
After hours: 1.58 Short-term: ★★☆☆☆ | Long-term: ★★☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, 12:26 a.m. EDT
BioVie (BIVI) is a high-risk speculative play on Parkinson's trial data that offers no dividend and faces technical resistance with negative short-term price forecasts. Recent volatility around a $12M equity offering and a 50% intraday drop indicate thin liquidity and sensitive sentiment. While undervalued relative to its balance sheet, the negative earnings, negative cash flow, and model-predicted downside make it unsuitable for income or conservative investors. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.107640 |
| AutoARIMA | 0.107641 |
| MSTL | 0.108248 |
| AutoTheta | 0.176250 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 45% |
| H-stat | 8.08 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.123 |
| Excess Kurtosis | -0.19 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.635 |
| Market Cap | 11,914,360 |
| Forward P/E | -0.36 |
| Beta | 0.56 |
| Website | https://bioviepharma.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.8073171 |
| Address1 | 680 W. Nye Lane |
| Address2 | Suite 204 |
| All Time High | 4,609.8 |
| All Time Low | 1.06 |
| Ask | 2.02 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 59,450 |
| Average Daily Volume3 Month | 85,050 |
| Average Volume | 85,050 |
| Average Volume10Days | 59,450 |
| Beta | 0.561 |
| Bid | 1.13 |
| Bid Size | 2 |
| Book Value | 2.555 |
| City | Carson City |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 1.58 |
| Current Ratio | 7.25 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 1.59 |
| Day Low | 1.56 |
| Debt To Equity | 1.635 |
| Display Name | BioVie |
| Dividend Date | 1,574,380,800 |
| Earnings Timestamp End | 1,778,529,600 |
| Earnings Timestamp Start | 1,778,529,600 |
| Ebitda | -17,968,812 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | 0.463 |
| Enterprise Value | -8,311,310 |
| Eps Forward | -4.41 |
| Eps Trailing Twelve Months | -3.28 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 1.3508 |
| Fifty Day Average Change | 0.2292 |
| Fifty Day Average Change Percent | 0.16967723 |
| Fifty Two Week Change Percent | -80.731705 |
| Fifty Two Week High | 13.2 |
| Fifty Two Week High Change | -11.62 |
| Fifty Two Week High Change Percent | -0.880303 |
| Fifty Two Week Low | 1.06 |
| Fifty Two Week Low Change | 0.5200001 |
| Fifty Two Week Low Change Percent | 0.49056616 |
| Fifty Two Week Range | 1.06 - 13.2 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,600,435,800,000 |
| Float Shares | 7,500,844 |
| Forward Eps | -4.41 |
| Forward P E | -0.35827667 |
| Free Cashflow | -8,277,755 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 13 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.00357 |
| Held Percent Institutions | 0.15636 |
| Implied Shares Outstanding | 7,540,734 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,751,241,600 |
| Last Split Date | 1,751,846,400 |
| Last Split Factor | 1:10 |
| Long Business Summary | BioVie Inc., a clinical-stage biopharmaceutical company, develops drug therapies to treat neurological and neurodegenerative disorders, and advanced liver disease in the United States. The company develops BIV201, that is in phase 2 for the treatment of ascites due to chronic liver cirrhosis. It also develops NE3107 that is in Phase III clinical trial for the treatment of patients with mild to moderate Alzheimer's disease; and in Phase 2 clinical trial to treat Parkinson's disease, as well as for the long COVID program. The company was formerly known as NanoAntibiotics, Inc. and changed its name to BioVie Inc. in July 2016. BioVie Inc. was incorporated in 2013 and is headquartered in Carson City, Nevada. |
| Long Name | BioVie Inc. |
| Market | us_market |
| Market Cap | 11,914,360 |
| Market State | POST |
| Max Age | 86,400 |
| Message Board Id | finmb_242387715 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -17,478,136 |
| Next Fiscal Year End | 1,782,777,600 |
| Non Diluted Market Cap | 11,914,359 |
| Open | 1.58 |
| Operating Cashflow | -14,322,561 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 775 888 3162 |
| Post Market Change | 0.0 |
| Post Market Change Percent | 0.0 |
| Post Market Price | 1.58 |
| Post Market Time | 1,776,812,320 |
| Previous Close | 1.58 |
| Price Hint | 4 |
| Price To Book | 0.6183953 |
| Profit Margins | 0.0 |
| Quick Ratio | 6.899 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.0 |
| Regular Market Change Percent | 0.0 |
| Regular Market Day High | 1.59 |
| Regular Market Day Low | 1.56 |
| Regular Market Day Range | 1.56 - 1.59 |
| Regular Market Open | 1.58 |
| Regular Market Previous Close | 1.58 |
| Regular Market Price | 1.58 |
| Regular Market Time | 1,776,801,601 |
| Regular Market Volume | 42,862 |
| Return On Assets | -0.47197 |
| Return On Equity | -0.80739 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 7,540,734 |
| Shares Percent Shares Out | 0.020499999 |
| Shares Short | 154,206 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 141,788 |
| Short Name | BioVie Inc. |
| Short Percent Of Float | 0.020599999 |
| Short Ratio | 2.31 |
| Source Interval | 15 |
| State | NV |
| Symbol | BIVI |
| Total Cash | 20,540,584 |
| Total Cash Per Share | 2.724 |
| Total Debt | 314,915 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -3.28 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.20245 |
| Two Hundred Day Average Change | -0.62245 |
| Two Hundred Day Average Change Percent | -0.2826171 |
| Type Disp | Equity |
| Volume | 42,862 |
| Website | https://bioviepharma.com |
| Zip | 89,703 |